NEW YORK (GenomeWeb News) – Affymetrix founder, chairman, and CEO Stephen Fodor will relinquish his CEO responsibilities as of Jan. 1, 2009, the company said today.
 
Fodor will serve as full-time executive chairman, a position in which he will “identify and advance new platform technologies and explore new market opportunities for the company,” Affymetrix said in a statement.
 
Kevin King, president of Affymetrix, will become CEO and a member of the board of directors on Jan. 1.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.